Disease-modifying treatments for multiple sclerosis may affect the risk of contracting COVID-19


  • B-cell depleting disease-modifying treatments (DMTs) may increase the susceptibility of patients with multiple sclerosis (MS) to COVID-19 infection.

Why this matters

    The incidence of respiratory infections is higher in patients with MS and DMTs may increase the risk of infections, including COVID-19, in this patient population; however, the association of demographics, disability level and the use of DMTs with the risk of infection is unknown.